Review



cd44 apc  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems cd44 apc
    Cd44 Apc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/pm41631682-53-21-27?v=R%26D+Systems
    Average 93 stars, based on 16 article reviews
    cd44 apc - by Bioz Stars, 2026-08
    93/100 stars

    Images



    Similar Products

    apc anti mouse cd44  (Miltenyi Biotec)
    94
    Miltenyi Biotec apc anti mouse cd44
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Apc Anti Mouse Cd44, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/pmc13006431-43-0-6?v=Miltenyi+Biotec
    Average 94 stars, based on 1 article reviews
    apc anti mouse cd44 - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    ‒ anti cd44 apc vio779  (Miltenyi Biotec)
    95
    Miltenyi Biotec ‒ anti cd44 apc vio779
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    ‒ Anti Cd44 Apc Vio779, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/pm42098128-440-54-58?v=Miltenyi+Biotec
    Average 95 stars, based on 1 article reviews
    ‒ anti cd44 apc vio779 - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    cd44 apc  (Miltenyi Biotec)
    95
    Miltenyi Biotec cd44 apc
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Cd44 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/pm41913277-83-40-41?v=Miltenyi+Biotec
    Average 95 stars, based on 1 article reviews
    cd44 apc - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    cd44 apc  (R&D Systems)
    93
    R&D Systems cd44 apc
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Cd44 Apc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/pm41631682-53-21-27?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    cd44 apc - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier
    apc anti cd44  (Miltenyi Biotec)
    95
    Miltenyi Biotec apc anti cd44
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Apc Anti Cd44, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/pmc12757047-266-19-21?v=Miltenyi+Biotec
    Average 95 stars, based on 1 article reviews
    apc anti cd44 - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    cd44 apc cy7  (Cytek Biosciences)
    93
    Cytek Biosciences cd44 apc cy7
    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic <t>CD44</t> + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .
    Cd44 Apc Cy7, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd44+apc/pm41094529-56-23-24?v=Cytek+Biosciences
    Average 93 stars, based on 1 article reviews
    cd44 apc cy7 - by Bioz Stars, 2026-08
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic CD44 + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .

    Journal: Cell Reports Medicine

    Article Title: Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy

    doi: 10.1016/j.xcrm.2026.102632

    Figure Lengend Snippet: Val-ILs and αPD-1 affect the growth and spread of breast tumor cells 10 6 4T1 cells were transplanted through i.d. injection into the mammary gland of female BALB/c mice. When tumors reached 50 mm 3 , mice were i.v. injected with Val-ILs (10 12 NPs) and i.p. injected with αPD-1 (200 μg) on days 6, 9, and 12. Analyses were performed on day 15 (A–E). (A) Tumor growth volumes measured in vivo. (B) Image of tumors isolated ex vivo from the mammary gland of mice (two independent in vivo experiments). Val-ILs-Combo was efficient in reducing the tumor volumes, and the combination of Val-ILs-Combo and αPD-1 was even more efficient. Mice without breast tumors are identified with a black cross. (C) FC on TAM cells in the TME and macrophages in the spleen, to identify M1-like and M2-like phenotypes. (D) Images of mice measured with in vivo imaging system technology showing the detection of bioluminescent 4T1 cells in the mammary gland, following treatment with Val-ILs-Combo and/or αPD-1. (E) FC was used to detect metastatic CD44 + GFP + 4T1 cells spreading to distant organs following treatment. Examples of FC plots and a heatmap displaying the mean percentages. Undetected (ud) indicates the absence of detectable tumor 4T1 cells. (F) On day 30, tumor-free mice were rechallenged with a secondary injection of 10 6 4T1 cells into the contralateral mammary gland. Tumor growth was monitored to evaluate the establishment of a protective anti-tumor memory. The number of mice used per group is indicated on the figure, data are shown as means ± SD, and p values are compared to Val-ILs-IgG + αIgG or between the different groups and are calculated using one-way ANOVA with Tukey’s multiple comparisons test. See also .

    Article Snippet: APC anti-Mouse CD44 (Clone REA664) , Miltenyi Biotec , Cat# 130-119-121; RRID: AB_2751628.

    Techniques: Injection, In Vivo, Isolation, Ex Vivo, In Vivo Imaging